Treatment Model Linked to Drop in Post-Incarceration Overdoses
WEDNESDAY, Feb. 21, 2018 -- Introduction of a new model of screening and protocoled treatment with medications for opioid addiction treatment (MAT), including methadone, buprenorphine, or naltrexone, is associated with a reduction in postincarceration deaths from overdose, according to a research letter published online Feb. 14 in JAMA Psychiatry.
Traci C. Green, Ph.D., from the Warren Alpert Medical School of Brown University in Providence, R.I., and colleagues conducted a retrospective analysis of all unintentional deaths from overdose occurring from Jan. 1 to June 30, 2016, and from Jan. 1 to June 30, 2017, before and after the new model was launched at the Rhode Island Department of Corrections.
The researchers identified 179 overdose deaths from Jan. 1 to June 30, 2016, compared with 157 during the same period in 2017, representing a 12.3 percent reduction. Most deaths from overdose were related to fentanyl. Over time, the total number of admissions and releases from incarceration were similar; the provision of naloxone to inmates after release from incarceration declined, while there was an increase in monthly receipt of MAT after release from incarceration. In the 2016 period, 14.5 percent of those who died of an overdose were recently incarcerated, compared with 5.7 percent in the 2017 period, a 60.5 percent reduction in mortality.
"Identification and treatment of opioid use disorder in criminal justice settings with a linkage to medication and supportive care after release from incarceration is a promising strategy to rapidly address the high rates of overdose and opioid use disorder in the community," the authors write.
One author disclosed financial ties to Alkermes.
© 2020 HealthDay. All rights reserved.
Posted: February 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.